The most common nonfamilial forms of amyloidosis that involve the kidney are the AL (amyloid light chain) and AA (serum amyloid A) types. These two forms require different treatment strategies ...

Among 83 patients receiving biologic agents for their underlying conditions and who had serum amyloid-α (AA) amyloidosis affecting the kidneys, from 60% to 88% did not develop end-stage renal disease ...

Alzheimer’s disease is a long, slow neurodegenerative calamity, and scientists are still hunting for blood biomarkers that reflect all its specific stages. At the Clinical Trials on Alzheimer’s ...

The first drugs against Alzheimer's disease that are intended to slow down the progression of the condition will soon be authorized in Germany. On November 14, 2024, the EMA granted approval for ...

The study showed significant reductions in serum TTR levels in subjects after a single dose, with sustained effects over time ...

Brain volume loss linked to new Alzheimer’s immunotherapies, such as lecanemab, is caused by the removal of amyloid plaques rather than neuronal damage.

Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...

A loss of brain volume associated with new immunotherapies for Alzheimer's disease may be caused by the removal of amyloid plaques, rather than the loss of neurons or brain tissue, finds a study led ...

Okuda Y and Takasugi K (2006) Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis ... but suppression of serum AA levels is not always ...